Abstract: Novel inhibitors of Rho-kinases are disclosed.

Abstract: A method and apparatus for conducting a visual acuity test are provided. The method includes displaying a visual acuity test on a display device (20) that is initiated by a controller (16) such as a handheld keypad controller (16), which is operatively associated with the computer-processing unit (12). The patient's eye is fixated using an eye fixation assessment on a display device during portions of the visual acuity test and is initiated by a controller such as a foot pedal controller (14), which is operatively associated with the CPU. Contrast sensitivity can also be evaluated on the display device by selectively altering the contrast of an image and background on the display device (20).

Abstract: The present invention provides an occluder with a plurality of flexible rings that comprise a self centering mechanism to keep the occluder properly centered in a defect. The self centering mechanism is located between the left and right sides of the occluder. Because the occluder remains properly centered, the chance that portions of the aperture will be exposed is reduced and the effectiveness of the occluder is increased.

Abstract: The present invention provides an occluder with a self centering system that keeps the occluder properly centered in a defect which allows the center of the occluder to remain properly positioned within the defect so that the left and right sides cover the entire defect which reduces the chance of blood shunting through the defect and increases the effectiveness of the occluder. The self centering system is comprised of a series of arms that provide tension to hold the right and left sides in place. The arms are shaped to provide a flexible intermediate zone comprising a left and a right conical shaped network, wherein each network extends from the right and left sides and narrows at the center section. The flexible intermediate zone centers the occluder and helps to hold it in place.

Abstract: Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

Abstract: An occlusion device having at least five arms. Though the number of arms is increased, the diameter of each arm is reduced. As a result, the increased number of arms provides the desired tension as the occlusion device is deployed and provides the desired strength to hold the occlusion device in place and properly occlude the defect. At the same time, the reduced diameter of the arms improves the cycle life of the occlusion device. Furthermore, the increased number of arms provides for better sealing across the defect and reduces residual shunting.

Abstract: Compounds of the formula (I) are disclosed which are large conductance calcium activated potassium channel openers (BK channels openers) and are useful in the treatment of urinary tract disorders: or a pharmaceutically acceptable salt thereof.

Abstract: The inventive methodology provides an integrated plug and play solution designed to protect home networks against spam, phishing emails, viruses, spyware as well as other similar threats. The described content filtering appliance can be used for processing of web and email traffic implemented and can be deployed as a stand-alone appliance. In one implementation, the content processing appliance utilizes backend content filtering provided by a remote scanning service accessed via a network. The system employs network level analysis and translation of content and executes various procedures to handle the network traffic. In an embodiment of the invention, the appliance is provided with an automatic remote updating capability, wherein the software and data used by the appliance can be updated remotely via a network. Finally, the appliance may also implement parental controls.

Abstract: This invention relates to an occlusion device for the heart, having an articulated center post which allows the device to better conform to the contours of the heart to increase sealing abilities and reduce breakage resulting from conformation pressure.

Abstract: Disclosed are load testing methods and systems with transaction variability and consistency.

Abstract: The present invention is an occlusion device having a collapsible frame which allows the occlusion device to be more easily centered in a defect and retrieved in situ. The occlusion device comprises a first post configured to be located on a first side of a defect, a second post configured to be located on a second side of the defect, and a fixation device connected to the first and second posts. The fixation device is used to hold the occlusion device in place across a defect, and comprises several segments. The segments are shaped so that each segment comprises a loop, causing the fixation device to resemble a “daisy design.

Abstract: This invention relates to an occlusion device for the closure of physical defects. The occlusion device is capable of self-centering itself in the defect. This allows the center of the occluder to remain properly positioned in the defect, while maintaining a low profile against the tissue.

Abstract: This invention relates to an occlusion device for the heart, having an articulated center post which prevents rotation of the individual occluder elements around the center post, while allowing the device to better conform to the contours of the heart to increase sealing abilities and reduce breakage resulting from conformation pressure.

Abstract: Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.

Abstract: This invention relates to an occlusion device for the heart, having an articulated center post which allows the device to better conform to the contours of the heart to increase sealing abilities and reduce breakage resulting from conformation pressure.

Abstract: Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

Abstract: The present invention is an occlusion device having a support hoop. The support hoop increases the ability of the occlusion device to form a seal around the defect and adds additional structural strength to the device by allowing distribution of pressure along a 360° continuum.

Abstract: An occlusion device having laminated polyvinyl alcohol sheets for occluding a defect. The laminated polyvinyl alcohol sheets provide an increased tear strength to the sheets that allows the device to be fully retrievable through the same catheter used to deploy it. The laminated sheets are created by obtaining thin sheets of polyvinyl alcohol foam, arranging the sheets on one another, and applying heat and pressure to laminate the sheets together.

Abstract: Compounds of this invention are non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, useful in treating bacterial infections.